key: cord-0829994-mst9cn89
authors: Behl, Tapan; Kumar, Sachin; Sehgal, Aayush; Singh, Sukhbir; Sharma, Neelam; Chirgurupati, Sridevi; Aldubayan, Maha; Alhowail, Ahmad; Bhatia, Saurabh; Bungau, Simona
title: Linking COVID-19 and Parkinson's disease: Targeting the role of Vitamin-D
date: 2021-10-19
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2021.10.042
sha: b8a7e69b7256c22f8d237b957f8c9d74166e6f9c
doc_id: 829994
cord_uid: mst9cn89

COVID-19 pandemic has a major effect on world health, particularly on individuals suffering from severe diseases or old aged persons. Various case studies revealed that COVID-19 might increase the progression of Parkinson's disease (PD). Coxsackievirus, dengue virus Epstein-Barr virus, hepatitis C virus, Japanese encephalitis, Western equine encephalomyelitis virus, West Nile virus, and human immunodeficiency virus have all been linked to the development of transient or permanent parkinsonism, owing to the induction of neuroinflammation/hypoxic brain injury with structural/functional damage within the basal ganglia. Coronavirus mainly infects the alveolar cells and may lead to acute respiratory distress syndrome. SARS-CoV-2 invades cells via the ACE2 receptor, which is widely expressed in the central nervous system, where the virus may precipitate or accelerate dementia. SARS-CoV-2 could enter the central nervous system directly by the olfactory/vagus nerves or through the bloodstream. Here, we talked about the importance of this viral infection in terms of the CNS as well as its implications for people with Parkinson's disease; anosmia & olfaction-related impairments in COVID-19 & PD patients. And, also discussed the role of vitamin D to sustain the progression of Parkinson's disease and the COVID-19; regular vitamin D(3) consumption of 2000–5000 IU/day may reduce the risk and severity of COVID-19 in parkinsonian patients.

Stanley Fahn and colleagues revealed a link among the existence of antibodies to OC43 and 229E coronaviruses (causes flu) in the CSF and PD nearly two decades before the current pandemic [18] . Previously coronaviruses were already found to cause neurological symptoms and CSF invasion in children on rare occasions [19, 20] . Medical information reveals evidence of a relationship between viral infections and PD [21] . The most recognised case is postencephalitic PD, which occurred in the course of the encephalitic lethargica wave in 1918, which coincided with the influenza A virus H1N1 (Spanish Flu epidemic) [22] . The cause of encephalitis lethargica, however, is still unknown after more than a century. While a causative function for the influenza A virus H1N1 in the progress of PD after encephalitic lethargica has yet to be shown, there is evidence of a link between virus influenza A infection and the temporary PD development [23, 24] . Many people who survived the avian flu developed PD [25] . New research suggests that the hepatitis C virus is neurotropic and can replicate in the CNS. Parkinsonism is infrequently seen in HCV patients. Patients with hepatitis C virus had a considerably increased chance of getting PD, according to Tsai et al., who conducted a large countrywide population-based study [26] . Cognitive impairment, tiredness, and sadness are all common symptoms of chronic hepatitis C virus infection. Recent findings suggest a molecular mimicry pathway between herpes simplex virus 1 and α-synuclein in the membranes of SnPc dopaminergic neurons. When PD patients were compared to healthy controls, there was a difference in the level of autoantibodies that recognised herpes simplex virus 1. The antibodies were able to cross-react with the homologous α-synuclein epitope, suggesting that they could promote α-synuclein aggregation [25] . These findings imply that herpes simplex virus 1 may have a role in activating an immunological response in PD, leading to the death of dopaminergic neurons. The dengue virus is a single-stranded enclosed RNA virus that belongs to the flavivirus family. The disease is spread by Aedes mosquitoes. The symptoms of dengue infection can range from a moderate viral fever to dengue hemorrhagic fever and shock. It is also a multisystem disease with a wide range of unusual symptoms [27] . One example is neurological symptoms. Meningoencephalitis, Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Guillain-Barre Syndrome are a few of them. Coxsackie, human immunodeficiency, Western equine encephalomyelitis, and Japanese encephalitis virus are linked to the progress of temporary or permanent PD, mostly due to neuroinflammation induction or brain damage due to hypoxia (Table 1) . Furthermore, conflicting research advises that previous Epstein-Barr, hepatitis C, herpes simplex 1, influenza A, and varicella-zoster viral infections can raise the likelihood of getting PD in the long run ( Figure 1 ). After finding the genetic variants associated with the pathogenesis of PD, the involvement of "environmental" aspects serving as extrinsic stimulators towards the neurodegeneration in vulnerable persons has become more recognised [28, 29] . 

The world appears to have come to a virtual halt in recent months. Several nations have made strenuous efforts to decline the spread of the virus SARS-CoV-2 as it remains spreading worldwide. Social alienation is one of them, as is a complete social and economic lockdown in J o u r n a l P r e -p r o o f some countries. The impact of the COVID-19 catastrophe on the existence of the most vulnerable peoples, medical services, and the global economy is palpable. Here, special worries about the elevated susceptibility of people with prolonged diseases include neurological illnesses like PD [30] . Undoubtedly, PD is common in older, and it may wreak havoc on respiration, as evidenced by the greater risk of pneumonia seen in individuals with severe PD.

A PD diagnosis may contribute to greater breathing problems or an adverse consequence following a COVID-19 infection. The "instant" effects of SARS-CoV-2 infection on parkinsonian persons have been widely discussed, including in webinars and educational webpages produced by patient organisations all around the world. COVID-19, on the other hand, has the potential to have far-reaching consequences for PD patients [31] . Here, we will look at some of the less visible but possibly deadly effects of the COVID-19 epidemic on PD patients. More particularly, how preventive social actions to reduce the danger of infection have radically altered the lifestyle of many victims. We also discuss how this situation is already resulting in new programs that provide encouragement and guidance to patients and their families. The SARS-CoV-2 outbreak has drastically altered patients' daily activities in a relatively short period. Such sudden change necessitates a dynamic adjustment to the changed situations, a psychological operation that relies on adequate dopaminergic function. Many parkinsonian patients exhibit cognitive and motor inconsistency in response to the depletion of dopamine in the nigrostriatal region, which is the disease's pathophysiological substrate [32, 33] . Moreover, the adaptation dependent on dopamine is a need for effective coping. Its absence gives rise to loss of self-control & a greater risk of psychological problems such as anxiety [34] . This could clarify why stress-linked psychological problems like anxiety & depression are widespread in parkinsonian patients, affecting patients up to 30-40 per cent, even when they are not in crisis [35] . As a result, the parkinsonian pathophysiology sets patients at higher risk of extreme stress. Progression of this condition might be a part of the COVID-19 pandemic's many hidden miseries. Notably, higher stressful situations during the COVID-19 pandemic might have many short-and long-term negative repercussions for people with PD. Firstly, increasing psychological stress can exacerbate numerous motor functions such as tremors, dyskinesias, and gait freezing while decreasing the efficiency of the dopaminergic medicaments [36] [37] [38] . Second, greater stress has the potential to reveal a hidden hypokinetic stiff condition by diminishing compensating processes [39, 40] . Surprisingly, some variables defend against stress's negative consequences. This is referred to as "resilience," which is defined as the capability to preserve or rapidly regain mental health in the face of difficulty. Personal attributes like creativity, optimism, intelligence, and a sense of social care and the environmental connection, are all linked to resilience [42] . The present situation provides an opportunity to examine who copes better with the present circumstances versus those who have the most difficulty and the factors that influence these variations. It is also worth noting that particular treatments for stress reduction, such as mindfulness-based programmes, are available. Mindfulness has been found in many recent studies to decrease anxiety and depression and enhance motor functions [43] . These classes are normally provided in patient groups, although they might be available online. These web-based alternatives may also help alleviate feelings of isolation, which is another unintended result of the current pandemic. Children recommend to leave visiting their PD-affected parents if possible, and grandkids should be at a distance. Perhaps social interactions as a result of homebased nursing care have decreased [30] . Digital alternatives are critical for reducing feelings of isolation and providing peace and happiness to PD patients confined within their homes.

Jon Stoessl et al. write in a recent editorial focused on movement disorders around the world during COVID-19 that there is no clinical evidence with movement disorders at higher risk of coronavirus infection than others of the same age and comorbidity [44] . Fasano et al. undertook a single-centre case-control study assessing clinical predictors of COVID-19 infection and outcome in a reasonably unselected and big homogeneous cohort of PD patients from one of Milan's largest tertiary facilities to answer rising issues on this topic. They found 105 PD patients, 32 confirmed COVID-19 cases, and 73 suspected COVID-19 cases [45] . COVID-19 risk, morbidity, and mortality in patients with mild to moderate PD do not differ from the normal population, according to their findings.

The existing COVID-19 epidemic presents a chance to test the theory that virus invasion might cause dementia. SARS-CoV-1, a pathogenic homolog of SARS-CoV-2, invades the brain via ACE2 and may be neurotropic as well. SARS-CoV-2 too accesses cells through the ACE2R [46] , which is present in the CNS, along with the nigrostriatal region, and here the virus may [53] . Proteins from SARS-CoV-2 can bind to human protein transportation molecules.

ORF8, one of these proteins, is associated with endoplasmic reticulum control. Unless SARS-CoV-2 may disrupt proteostasis by attaching to ORF8 and causing abnormal endoplasmic reticulum protein transportation, α-synuclein could clump together uncontrollably [54] . 

Some research has already suggested a connection between COVID-19 and neurological diseases, including PD [55] . These conclusions are based on a number of findings:

coronaviruses' potential to penetrate the CNS via the sinuses, resulting in neurodegeneration, as demonstrated in animal experiments [56] ; a typical prodromal characteristic of PD is hyposmia and has been widely described in COVID-19 subjects lacking nasal obstruction [57] ;

in COVID-19, lesions of the basal ganglia may arise as a result of a thromboembolic encephalopathy [58] ; the existence of antibodies against various coronaviruses which gives rise to the flu in the PD subjects compared to fit volunteers shows that virus invasion may play a role in the aetiology of the disease [18]; there have been reports that ACE2 is present in numerous systems in the body, however as mentioned above, more neuropathological research is needed. Because this protein activates interferons, it will be necessary to look at people who have CNS encephalitis or inflammation [47] ; recent findings of fainting without any aberrant rhythms on cardio equipment investigation show a function of neurally-mediated fainting versus orthostasis, emphasised the role of these studies for PD subjects frequently experiencing autonomous dysfunction [59] ; A case study record of a subject that had myoclonus and an acute although apparently recoverable hypokinetic stiff condition, and DaTscan revealing hyposmia and decreased dopaminergic loading in the putamen [60] ; the angiotensin system, that has been linked with COVID-19 development, could have a role in the neural inflammation and degeneration pathways seen in PD [61]; proteins from SARS-CoV-2 may engage to specific proteins implicated in biochemical processes that cause protein homeostasis to fail [54] , resulting in the accumulation of misfolded proteins ( Figure 2) ; the production of cytokines may stimulate local immune cells within CNS & allow them to infiltrate causing brain cell injury.

This can happen via the cell selection that identifies important antigens from the infections, via the common excitation of cytotoxic cells that identify certain antigens, such as α-synuclein derived autoantigens that have a link to PD, dementia (Lewy Body), atrophy & sclerosis.

Elevated concentrations of TNF and IL-1-ß are linked to a higher risk of PD, whereas anti-TNF biosimilars and NSAIDs lower the risk [64] . COVID-19 is now being studied with anti-TNF biosimilars. [22] . They discovered how this influenza virus strain attacked neurons immediately, with a preference for pathways involved in PD. Following recovery from the virus invasion, the mice developed ataxia, bradykinesia, convulsion, dopaminergic neuronal loss, primary neuron inflammation, microgliosis, and an increased expression of α-synuclein [65] .

The olfactory epithelium is hypersensitive to changes in the external environment and vulnerable to chemical sensation loss and irritation [66] . In the analysis of odour data, the olfactory bulb acts as a bridge between the nasal epithelium and the brain. Olfaction depends hurdle. In addition, more research is needed to understand neurogenesis as well as the pathways that overlap with other neurological illnesses in the COVID-19 subjects' brains [69] . Upper respiratory tract illness is thought to be linked with olfactory bulb impairment in general.

However, independent of the beginning of respiratory dysfunctioning, anosmia caused by olfactory bulb disease has been described in most COVID-19 occurrences. As a result, the WHO has identified anosmia as a separate primary indication of SARS-CoV-2 [70] [71] [72] .

Anosmia was also long known as PD's pre-clinical indicator. It is worth noting that, unlike other nerve cells in human brains, sensory neurons which exhibit the olfactory receptors crucial for odour are constantly renews entire life. Through the development of axon coupling within the glomerular layer, the sensory nerves of the nasal epithelium transmit excitable connections with the granular cell layer's inhibitory interneurons of the bulb in the olfaction system [73] .

Notably, during adulthood, olfactory receptors within the nasal epithelium are reactive for juvenile neuron indicators like doublecortin. Matured neurogenesis leads to the formation of GABAergic interneurons (inhibitory type) in the granular cell layer of the olfactory bulb. In contrast, the inhibitory interneurons have a crucial part in the synaptic transmission of sensory nerve cells [74] . Furthermore, sensory neurons' axon processing in the glomerular layer appears to be vital in olfactory categorisation. The continuous production of dopaminergic nerve cells occurs through neural stem cells, and neural progenitors seem crucial [75] . Thus, in the physiological environment, the control of olfactory neurogenesis gives a pathway towards smell sensation. It is worth noting that dopamine deficiency in the J o u r n a l P r e -p r o o f matured brain seems to affect the mitotic cells number in the forebrain of people with PD and experimental animals. In autopsy brain samples of PD non-dementia sufferers, a weak connection was found among the duration of illness and the amount of Musashi-positive neural stem cells within the subventricular region [76] . Furthermore, it is confirmed that the autopsy brain having Lewy body has a lower amount of progenitor cells and Musashi-positive neural stem cells within the subventricular region. Furthermore, decreased neurogenesis inside the olfactory bulb has been shown in numerous parkinsonian animal models [77] . Inflammation in the neurons tends to affect neurogenesis in many neurodegenerative diseases, such as PD [78] . The adult brain's neurogenic capacity stops when dopamine production reduces. Adult neurogenesis appears to be aided by blocking neuroinflammation; consequently, the replenishing of the olfactory bulb's dopaminergic neurons compensation and odour sensation restores in PD.

Vitamin D receptors are widely distributed all over the body, and it is thought to have a role in various key activities and diseases. Vitamin D imbalance has a link to various diseases, like cardiovascular disease, hypertension, cognitive decline, diabetes, inflammation, immunological dysregulation, some cancers, and osteoporosis. Surprisingly, the majority of these diseases have a link with growing older [79, 80] . The causality direction in these interactions is still unknown. On the other hand, many studies have demonstrated that reaching and ensuring good vitamin D levels can assist clinical outcomes and/or lower the risk of developing common diseases. Past researches on vitamin D and its effect on disease, particularly respiratory tract disorders such as influenza, has yielded inconsistent results [81] .

There are few large-scale, randomised controlled trials in the contemporary environment, [82, 83] . Vitamin D has a number of functions, mostly in innate immunity.

Activated vitamin D promotes human beta-defensin 2 (HBD2) peptide and cathelicidin expression in combination with toll-like receptors [84] . The bacterial cell membrane disruption occurs due to cathelicidin (LL-37). This feature is believed to apply to viruses, especially Vitamin D could also assist the transfer of inflammatory mediators to the infection site by increasing capillary permeability. It is also hypothesised to be involved in the management of various cell junction types. The body's first defence mechanism against infections is strong physical barriers created by endothelial cell junctions. In addition, vitamin D and the stimulation of its receptors produce unique natural killer (NK) T cells, which serve as a link to adaptive immunity [83] . Vitamin D could have antioxidant qualities and also the potential to lengthen telomeres and stabilise DNA. Vitamin D also has a link to improved immunity including both types of symptoms that are motor and non-motor [91] . Sleeman et al., for example, found that age, motor score, dopaminergic drug dose, and baseline blood 25-Hydroxy Vitamin D3 levels all predicted motor disability intensity at 36 months, with lower D3 levels linked with worsening development [92] . Falls may also be greatly prevalent in PD persons that have balance issues, postural instability, and reduced motor function. Vitamin D deficiency disrupts calcium homeostasis, increasing the chances of bone fractures. A serious fall or fracture can significantly decrease a patient's quality of life if they have Parkinson's disease.

Furthermore, Peterson et al. found that better neuropsychiatric results were linked to high levels of 25-Hydroxy Vitamin D3 in the blood among Patients with PD without severe dementia [93] .

This was particularly true when it came to verbal fluency and memorisation. Vitamin D may also help to reduce anxiety, according to the group. Vitamin D supplementation may lower the chances of major injury from falls, enhance bone health, recover cognitive power, and reduce stress in PD patients, resulting in higher life quality and a slow progression of the disease [94] .

Advance medical planning is required in the COVID-19 pandemic scenario to accomplish patient care goals while avoiding significantly undesirable procedures, including catheterisation, ventilation, and ICU admissions [95] . During regular consultations, healthcare providers should advance medical planning with PD patients and their families and discuss treatment goals. If a PD patient acquires COVID-19 and needs to be admitted to the hospital, the advance directive must precede the patient [96] . In some nations, advanced medical planning forms may provide a free text field where practitioners can record the expressed goals of the patient and family away from the level of care terms [97] .

A number of recent papers go into great detail into the COVID-19 epidemic's impact on the common public. Furthermore, it is envisaged that antibody assays for universal immunity testing in large groups will be available shortly, permitting us to estimate the spread of infection and fatality rate more correctly. As coronavirus is a deadly virus that is a key concern all over the world, much more research work is needed to know about the virus transformation from one strain to another with developed antibiotic resistance.

The COVID-19 pandemic has triggered an unparalleled global disaster for the elderly.

Symptoms are varied, possibly due to pre-existing illnesses and in part due to diverse mechanisms of viral entry and the existence of T cells that are reactive to previous coronavirus infections. On the other hand, this worldwide crisis may substantially impact our patients with Parkinson's disease and other movement disorders, leading to greater adoption of telemedicine consultations and assessments. Vitamin D can help out the patients with COVID-19 and PD.

Vitamin D3 supplementation may assist in improving the motor and non-motor symptoms of PD, therefore enhancing the quality of life. Although more research is needed, daily vitamin D3 supplementation of 2000-5000 IU/day in people with PD may help to reduce the risk and severity of COVID-19.

Is COVID-19 a perfect storm for Parkinson's disease

When does Parkinson's disease begin? From prodromal disease to motor signs

Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies

Triggers, facilitators, and aggravators: redefining Parkinson's disease pathogenesis

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Viral load of SARS-CoV-2 in clinical samples

Presumed asymptomatic carrier transmission of COVID-19

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in

Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis

Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child

Viral parkinsonism

Evidence for an enterovirus as the cause of encephalitis lethargica

Encephalitis lethargica: 100 years after the epidemic

Infectious etiologies of parkinsonism: pathomechanisms and clinical implications

Hepatitis C virus infection as a risk factor for Parkinson disease: a nationwide cohort study

Post encephalitic parkinsonism following dengue viral infection

Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries

The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis

The impact of the COVID-19 pandemic on

Increased dependence of action selection on recent motor history in Parkinson's disease

Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective

Stress-induced plasticity and functioning of ventral tegmental dopamine neurons

What a neurologist should know about depression in Parkinson's disease

The functional network signature of heterogeneity in freezing of gait

Predictors of freezing in Parkinson's disease: a survey of 6,620 patients

Cognitive stress reduces the effect of levodopa on

Parkinson's resting tremor

Can stress trigger Parkinson's disease

Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: A randomized clinical trial

Parkinson's disease patients in times of humanitarian crisis: the COVID-19 experience

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system

SARS-CoV-2: at the crossroad between aging and neurodegeneration

COVID-19 and Parkinson's Disease: Are We Dealing with Short-term Impacts or Something Worse

Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Can the 2019 novel coronavirus cause

Parkinson's disease

Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Basal ganglia involvement and altered mental status: a unique neurological manifestation of coronavirus disease

Syncope as the presenting symptom of COVID-19 infection

Acute hypokinetic-rigid

Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis

Inflammatory effects of highly pathogenic H5N1

influenza virus infection in the CNS of mice

Olfaction: anatomy, physiology, and disease

COVID-19 and Parkinson's disease: Defects in neurogenesis as the potential cause of olfactory system impairments and anosmia

Novel measure of olfactory bulb function in health and disease

Neuropathological features of Covid-19

Olfactory dysfunction as an early biomarker in Parkinson's disease

Olfactory disorders following upper respiratory tract infections

Olfactory dysfunction in COVID-19: diagnosis and management

A unique olfactory bulb microcircuit driven by neurons expressing the precursor to glucagon-like peptide 1

Regulation of adult neurogenesis by GABAergic transmission: signaling beyond GABAA-receptors

Differentiation of adult hippocampusderived progenitors into olfactory neurons in vivo

Neurogenic marker abnormalities in the hippocampus in dementia with Lewy bodies

Adult neurogenesis in neurodegenerative diseases

TGF-β signaling: a therapeutic target to reinstate regenerative plasticity in vascular dementia

The problems of vitamin d insufficiency in older people

The role of Vitamin D in the aging adult

Benefits and requirements of vitamin D for optimal health: a review

Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths

Vitamin D and influenza-prevention or therapy

Vitamin D and neonatal immune function

Exploring links between vitamin D deficiency and COVID-19

Association of seasonal serum

hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis

Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician's expectation be matched by the reality

A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter

The role of vitamin D in disease progression in early Parkinson's disease

Memory, mood, and vitamin D in persons with Parkinson's disease

Parkinson's disease and osteoporosis: basic and clinical implications

Innovative ICU physician care models: COVID-19 pandemic at NewYork-Presbyterian, NEJM Catalyst Innovations in Care Delivery

Cognitive Impairment and COVID-19 Hospital

The impact of COVID-19 on palliative care for people with Parkinson's and response to future pandemics

Exploring the Role of Orexinergic Neurons in